TKAI - Tokai Pharmaceuticals Fri 13'th Jan 2017
Stock analysis for Fri 13'th Jan 2017 (Updated daily)
Hold candidate since 2017-01-13
Tokai Pharmaceuticals Stock Analysis
No changes to the price of Tokai Pharmaceuticals in the last trading day. The price has risen in 5 of the last 10 days days and is up by 1.94% over the past 2 weeks.
Tokai Pharmaceuticals lays in the middle of a very wide and strong falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -17.2% during the next 3 months and, with 90% probability will hold a price between USD 0.55 and USD 0.96 at the end of this period.
A buy signal was issued from a pivot bottom point on Wednesday January 11, 2017, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Volume fell on the last day without any changes to the share price. This doesnâ€™t cause any direct divergence but may be an early warning and a possible "turning point".
Relative Strength Index (RSI)
RSI14 is 34 and the stock is currently not being overbought or oversold
Support & Resistance
Tokai Pharmaceuticals finds support from accumulated volume at USD 1.04, USD 1.03, and USD 1.01. On the upside the stock meets some resistance just above today's level from accumulated volume at USD 1.07, USD 1.08 and USD 1.21.
The stock is about to test the resistance from accumulated volume at USD 1.07 and this may cause the stock to take a minor break or get into a more sideways move for a few days.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved USD 0.06 between high and low, or 5.83%. For the last week the stock has had a daily average volatility of 5.89%.
Our recommended stoploss: USD 1.01 (-3.81%) ( based on support and risk)
Tokai Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy-recommendation. At the current level we recommend a hold or accumulate position awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Buy Candidate to a Hold/Accumulate.